Top

Published in:

01-10-2011

The New Era of C1-Esterase Inhibitor Deficiency Therapy

Authors: Louanne Marie Tourangeau, Bruce L. Zuraw

Published in: Current Allergy and Asthma Reports | Issue 5/2011

Abstract

Hereditary angioedema (HAE) is an autosomal dominant disorder clinically characterized by recurrent episodes of angioedema. Until late-2008, HAE therapy in the United States was largely limited to antifibrinolytic agents or attenuated androgens. Although these drugs decrease the number and severity of angioedema attacks, they are associated with significant dose-related adverse effects. Recent advances have dramatically changed the management of HAE. As a result, we are embarking on a new era of treatment for this condition that includes effective on-demand treatment of attacks as well as effective prophylactic treatment. Herein we discuss the various treatment options for C1-inhibitor deficiency, focusing on new developments and literature published over the past year, as well as the additional patient considerations that should be addressed when determining the most appropriate patient-specific treatment plan.

Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027–36.PubMedCrossRef

Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol. 2008;45(13):3536–44.PubMedCrossRef

Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213–7.PubMedCrossRef

Binkley KE, Davis 3rd A. Clinical, biochemical, and genetic characterization of a novel estrogen- dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106(3):546–50.PubMedCrossRef

Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286–9.PubMedCrossRef

Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75(4):349–54.PubMedCrossRef

Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C'1- esterase. Am J Med. 1963;35:37–44.PubMedCrossRef

Gadek JE, Hosea SW, Gelfand JA, Santaella M, Wickerhauser M, Triantaphyllopoulos DC, et al. Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med. 1980;302:542–6.PubMedCrossRef

Agostoni A, Bergamaschini L, Martignoni G, Cicardi M, Marasini B. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy. 1980;44:299–301.PubMed

10.

• Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801–8. This clinical trial was the first randomized, placebo-controlled investigation to show that plasma-derived C1INH concentrate was a safe and effective on-demand therapy for acute abdominal and facial HAE attacks. PubMedCrossRef

11.

Craig TJ, Wasserman RL, Levy RJ, Bewtra AK, Schneider L, Packer F, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol. 2010;30(6):823–9. PMCID: 2970824.PubMedCrossRef

12.

Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia. 2003;9(1):24–37.PubMedCrossRef

13.

• Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513–22. This study reported the results of two randomized, placebo-controlled trials showing that nanofiltered, pasteurized C1INH concentrate was effective for both on-demand and prophylactic use in HAE. PubMedCrossRef

14.

Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 Suppl):S51–S131.PubMedCrossRef

15.

Choi G, Soeters MR, Farkas H, Varga L, Obtulowicz K, Bilo B, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion. 2007;47(6):1028–32.PubMedCrossRef

16.

• Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. The Journal of Allergy and Clinical Immunology. 2010;126(4):821–7. e14. This study showed that recombinant C1INH therapy was safe and effective as on-demand therapy for acute HAE attacks. PubMedCrossRef

17.

Donaldson VH, Ratnoff OD, Da Silva WD, Rosen FS. Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. JCI. 1969;48:642–53.PubMedCrossRef

18.

Davis 3rd AE. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am. 2006;26(4):633–51.PubMedCrossRef

19.

Cochrane CG, Griffin JH. The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol. 1982;33:241–306.PubMedCrossRef

20.

Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis 3rd AE. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109(8):1057–63.PubMed

21.

Zuraw B, Yasothan U, Kirkpatrick P. Ecallantide. Nat Rev Drug Discov. 2010;9(3):189–90.PubMedCrossRef

22.

Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363(6):523–31.PubMedCrossRef

23.

• Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Annals of Allergy, Asthma & Immunology. 2010;104(6):523–9. This study reported that an engineered plasma kallikrein inhibitor was safe and effective as on-demand therapy for acute HAE attacks. CrossRef

24.

Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005;57(1):27–77.PubMedCrossRef

25.

Bork K, Yasothan U, Kirkpatrick P. Icatibant. Nature Reviews Drug Discovery. 2008;7:801–2.CrossRef

26.

• Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532–41. The results of this clinical trial indicated that icatibant was efficacious as on-demand therapy for moderate to severe HAE attacks. The article explores why one of the icatibant clinical trials failed. PubMedCrossRef

27.

Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Reshef A, et al. Results from FAST-3: a phase III randomized, double-blind, placebo-controlled, multicenter study of subcutaneous icatibant in patients with acute hereditary angioedema (HAE) attacks. J Allergy Clin Immunol. 2011;127(2 (Suppl)):AB1.CrossRef

28.

Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267–74.PubMedCrossRef

29.

Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, Rusicke E, Heller C, Klingebiel T. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion. 2009;49(9):1987–95.PubMedCrossRef

30.

Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. 2009;19(2):147–51.PubMed

31.

Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol. 2006;117(4):904–8.PubMedCrossRef

32.

Longhurst HJ, Farkas H, Craig T, Aygoren-Pursun E, Bethune C, Bjorkander J, et al. HAE international home therapy consensus document. Allergy, Asthma, and Clinical Immunology. 2010;6(1):22. PMCID: 2922091.PubMedCrossRef

33.

Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006;101(3):619–27.PubMedCrossRef

34.

Tourangeau LM, Castaldo AJ, Davis DK, Koziol J, Christiansen SC, Zuraw BL. Safety and efficacy of physician supervised self-managed C1 inhibitor individual replacement therapy. Int Arch Allergy Immunol 2011 (in press).

35.

Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. N Engl J Med. 1976;295:1444–8.PubMedCrossRef

36.

Drouet C, Desormeaux A, Robillard J, Ponard D, Bouillet L, Martin L, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008;121(2):429–33.PubMedCrossRef

37.

Maurer M, Magerl M. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG. 2011;9(2):99–107.PubMed

38.

Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med. 1972;286:808–12.PubMedCrossRef

39.

Jaffe CJ, Atkinson JP, Gelfand JA, Frank MM. Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. J Allergy Clin Immunol. 1975;55:386–93.PubMedCrossRef

40.

Jiang H, Zhang HM, Frank MM. Subcutaneous infusion of human C1 inhibitor in swine. Clin Immunol. 2010;136(3):323–8.PubMedCrossRef

41.

Martinez-Saguer I, Cicardi M, Aygören-Pürsün E, Rusicke E, Klingebiel T, Kreuz W. Pharmacokinetic Berinert P study of subcutaneous versus intravenous administration in subjects with moderate hereditary angioedema—the PASSION study. J Allergy Clin Immunol. 2011;127(2 (Suppl)):AB104.CrossRef

42.

Zuraw BL. HAE therapies: past present and future. Allergy, Asthma, and Clinical Immunology. 2010;6(1):23. PMCID: 2921104.PubMedCrossRef

43.

Bossi F, Fischetti F, Regoli D, Durigutto P, Frossi B, Gobeil Jr F, et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol. 2009;124(6):1303–10.e4. PMCID: 2798851.PubMedCrossRef

Title: The New Era of C1-Esterase Inhibitor Deficiency Therapy
Authors: Louanne Marie Tourangeau
Bruce L. Zuraw
Publication date: 01-10-2011
Publisher: Current Science Inc.
Published in: Current Allergy and Asthma Reports / Issue 5/2011
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-011-0213-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The New Era of C1-Esterase Inhibitor Deficiency Therapy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

The Emerging Role of Interleukin-1β in Autoinflammatory Diseases

Role of Sensitization to Mammalian Serum Albumin in Allergic Disease

Impact of Environmental Controls on Childhood Asthma

Effectiveness of Air Filters and Air Cleaners in Allergic Respiratory Diseases: A Review of the Recent Literature

Defects in Interleukin-17 Immunity in the Pathogenesis of Chronic Mucocutaneous Candidiasis

Basophils and Autoreactive IgE in the Pathogenesis of Systemic Lupus Erythematosus